Plus: H1 2026 M&A activity highlights recurring revenue models, and Iris Telehealth launches integrated behavioral health for women.
Roche’s Genentech and Astex Pharmaceuticals entered a global drug discovery and licensing agreement valued at up to $490 million, bringing new drug development focus to breast cancer. Separately, new research indicates breast cancer rates rose more than three percent annually among Asian American women over the past two decades, impacting clinicians and public health strategies. The femtech market also saw an $18 billion take-private deal and an $11.75 billion pharma deal in H1 2026, indicating buyer shifts toward established capabilities and recurring revenue. Five takes inside, plus a quick-hits roundup.
VIA FemTech Insider
The agreement is valued at up to $490 million. Roche’s Genentech and Astex Pharmaceuticals entered a global drug discovery and licensing agreement, with Roche making an upfront payment of $25 million. Over $465 million of the deal's value is tied to milestones. Genentech gains exclusive rights to compounds from Astex’s breast cancer research, plus tiered royalties on net sales of any commercialized medicines.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Queen Charlotte’s and Chelsea Hospital researchers tested a non-invasive high-powered ultrasound treatment for Twin-to-twin transfusion syndrome (TTTS) in 10 women, achieving blood flow blockage in 90% of treated vessels. Of the 20 babies, 12 survived, and five women required further treatment. This new method, which does not require inserting a needle or telescope, offers a less invasive option for treating TTTS, which impacts 10-15% of identical twins sharing a placenta. Femtech operators and clinicians focusing on maternal health may find value in non-invasive prenatal treatment technologies.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire Health
A new survey finds 30% of women received no specific treatment for stress from their providers. Telepsychiatry provider Iris Telehealth launched an Integrated Women's Behavioral Health Solution. This offers femtech operators and clinicians a new integrated care model for women's behavioral health.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Breast cancer rates rose more than three percent annually among Asian American women over the past two decades. The rates increased fastest among women under 50 and for advanced-stage disease; triple-negative breast cancer among Chinese American women rose over six percent annually between 2017 and 2022. This data suggests a need for targeted screening and prevention strategies for specific Asian American subgroups, particularly for early-onset and aggressive cancers.
Read the full story →
— The Luteal Editorial Team
VIA FutureFemHealth
An $18 billion take-private deal and an $11.75 billion pharma deal occurred in H1 2026. Buyers consistently targeted businesses with established capabilities, recurring revenue models, and strategic assets to strengthen broader healthcare platforms. Hologic went private to two large PE firms and two sovereign wealth funds, while Organon changed hands to a non-U.S. pharma. WPS, a health insurer, bought a clinical platform outright, expanding the buyer universe for women's health.
Read the full story →
— The Luteal Editorial Team